Understanding Sexually Transmitted Infections

Total Page:16

File Type:pdf, Size:1020Kb

Understanding Sexually Transmitted Infections Understanding Sexually Transmitted Infections Second Edition Administered by TABLE OF CONTENTS Introduction . page 1 Anatomy . page 2 Chlamydia . page 3 Bacterial Gonorrhea . page 4 Syphilis . page 5 Genital Herpes . page 6 Viral Hepatitis B . page 7 HIV (Human Immunodeficiency Virus) . page 8 HPV (Human Papillomavirus) . page 9 Pubic Lice & Scabies . page 10 Parasitic Trichomoniasis . page 11 Fungal Candidiasis (Yeast Infection) . page 12 Bacterial Vaginosis (BV) . page 12 Diagnosing Sexually Transmitted Infections . page 13 Barrier Methods . page 14 Treatment Summary • Bacterial . page 15 • Viral . page 16 • Parasitic & Fungal . page 17 INTRODUCTION Sexually Transmitted Infections Toward effective prevention, diagnosis and treatment Building awareness Informing your partner Bacterial In Canada and around the world, the trend is clear: Partner notification is critical to prevent further spread of STIs and prevent Chlamydia sexually transmitted infections (STIs) are on the rise. complications. It can be difficult to talk with a sexual partner about Gonorrhea Syphilis One of the primary defenses in the fight against STIs health problems, especially when they involve sexual health or a sexually is awareness. With the right information, individuals transmitted infection. However, it is important for anyone who suspects can make informed choices and better protect they’ve become infected or tests positive for an STI to ensure that current Viral themselves and their partners. and previous partners are made aware so they can seek medical attention Genital Herpes and treatment if needed. Hepatitis B An important reference HIV (Human Immunodeficiency Virus) Support is available This booklet is designed to optimize sexual HPV (Human Papillomavirus) health through STI prevention, testing/screening, If infected individuals are uncomfortable informing partners themselves, diagnosis, and timely treatment. they may ask their health-care professional to contact their partner(s) for them. This is done confidentially, meaning the patient’s name is never Parasitic A quick reference guide for health professionals, revealed to notified partners. Pubic Lice/Scabies counsellors and educators, it provides details Trichomoniasis of specific infections including infection Precautions characteristics, means of transmission, signs and Once an infection is detected, it is recommended that infected individuals symptoms, and methods for testing/screening, Fungal and their sexual partner(s) abstain from sexual activity until treatment is Candidiasis (Yeast Infection) treatment, management and prevention. complete (for treatable STIs), symptoms have subsided, and the infection Every case is different is cured (for curable STIs, confirmed through follow-up testing, as appropriate). Partners should consult a health professional for direction on Bacterial Vaginosis (BV) Many STIs are asymptomatic. Often, the only way to when sexual relations can be resumed. In the case of viral STIs, a health- detect an infection is through screening. care professional can offer safer-sex and risk-reduction tips to prevent Individuals who suspect they may have been transmission. Testing Methods infected should be encouraged to seek medical Condoms are important to reduce the risk of transmission, even if other attention immediately, rather than waiting for the methods of birth control are being used to prevent pregnancy. Prevention onset of visible symptoms. Treatment page 1 page 2 ANATOMY Female and Male Reproductive Systems Fallopian tube Ovaries Seminal vesicles Uterus Vas deferens Prostate gland Cervix Penis Vagina Fallopian tube Epididymis Ovary Uterus Testicles © sexualityandu.ca © sexualityandu.ca Bladder Clitoris Cervix Urethra Rectum Vagina © sexualityandu.ca BACTERIAL Chlamydia An often-asymptomatic infection that can lead to reproductive complications What is it? What are the Considerations and Chlamydia possible complications • The most common bacterial sexually signs and symptoms? Clear or milky urethral discharge may be a transmitted infection • Many infected individuals have no • Chlamydia is often associated with symptom of chlamydia in men. • Greatest number of infections found symptoms. other undetected or untreated in people 15 to 24 years old • Symptoms may occur from two to infections. • Can affect the cervix, urethra, and six weeks after initial exposure to the • Individuals infected with chlamydia occasionally the rectum, throat, and bacteria. are at increased risk of contracting and eyes transmitting HIV. Female How is chlamydia • Vaginal discharge Female transmitted? • Painful urination • Infection spreading to the uterus and Fallopian tubes (pelvic inflammatory • Chlamydia can be spread through • Lower abdominal pain unprotected oral, vaginal or anal sex disease) with an infected partner. • Vaginal bleeding after intercourse or • Risk of ectopic pregnancy between menstrual periods • Penetration and ejaculation are not • Infertility • Pain during intercourse © sexualityandu.ca required for transmission. • Chronic pelvic pain • Eye or rectal infection (rarely) • It can be passed from an infected • Rashes, sores and joint pain Although chlamydia is usually asymptomatic mother to her infant during birth, Male in women, it may present with inflammation causing lung and/or eye infections. Male of the cervix. • Clear, watery or milky urethral • Inflammation of the testicles, prostate discharge and scrotum • Itchy urethra • Rashes, sores and joint pain • Painful urination • Infertility (in rare cases) • Testicular pain • Eye or rectal infection (rarely) © sexualityandu.ca page 3 page 4 BACTERIAL Gonorrhea An often-asymptomatic infection that can lead to reproductive complications What is it? What are the Considerations and Gonorrhea • The second most common bacterial STI signs and symptoms? possible complications Yellowish-greenish discharge from the • Two-thirds of reported cases in Canada Female • Gonorrhea is often associated with penis may develop in men within two to are in men other undetected or untreated seven days of infection. Women are most often asymptomatic. infections. • Most common in individuals 15 to 29 Those that do exhibit symptoms may years old experience: • Individuals infected with gonorrhea are at increased risk of contracting and • Can affect the cervix, urethra, rectum, • Increased vaginal discharge throat, and occasionally the eyes transmitting HIV. • Painful urination • Often occurs as a co-infection with Female • Lower abdominal pain chlamydia • Infection spreading to the uterus and • Vaginal bleeding after intercourse or Fallopian tubes (pelvic inflammatory How is gonorrhea between menstrual periods disease) transmitted? • Pain during intercourse • Chronic pelvic pain • Gonorrhea can be spread through • Rectal pain, discharge or itching • Infertility unprotected oral, vaginal or anal sex © sexualityandu.ca with an infected partner. Male • Risk of ectopic pregnancy • Penetration and ejaculation are not Most men develop symptoms within • Systemic gonococcal infection Infected women who develop required for transmission. two to seven days of infection: Male symptoms may notice an increase in • It can be passed from an infected • Thick, yellowish-green discharge from vaginal discharge. mother to her infant during birth, penis • Inflammation of the testicles causing an eye infection. • Painful urination • Rashes, sores and joint pain • Testicular pain or swelling • Infertility (in rare cases) • Rectal pain, discharge or itching • Systemic gonococcal infection © sexualityandu.ca BACTERIAL Syphilis A staged STI once considered rare in Canada, sometimes called the great imitator What is it? Secondary syphilis Congenital syphilis Syphilis • An infection sometimes called the great A person may develop a range of symptoms Congenital syphilis can be a life- The first sign of syphilis in men is often imitator because signs and symptoms from two to 24 weeks after exposure, most threatening infection for infants. A a small, painless sore (chancre) on the mirror those of some common medical commonly: pregnant mother who has syphilis penis. conditions • A general feeling of being unwell can spread the infection through • Progresses in stages the placenta to the unborn child. To • A rash anywhere on the body and can decrease the risk of the unborn child • Infectious in the first year after include the palms of the hands or soles of becoming infected, the pregnant contraction the feet mother should be treated with How is syphilis transmitted? • Patchy hair loss antibiotics as early as possible. • Through oral, vaginal or anal sex with an • Flat, smooth warts in the genital area (not Considerations and infected partner the same as those caused by HPV) possible complications • Through direct contact with bacteria Early latent syphilis • Syphilis increases the risk of contained in syphilitic sores or rashes Is asymptomatic, but for the first year transmitting or becoming infected • In rare cases, from sharing unclean after infection lesions or rashes of with HIV. needles or receiving a blood transfusion secondary syphilis can recur and the • Response to treatment must be • From an infected mother to her fetus, infection can be transmitted. monitored by blood testing over © sexualityandu.ca time to ensure effectiveness, which can result in fetal death or Late latent syphilis congenital syphilis (causing birth defects) especially in HIV-infected The chancre sore appears where the Late latent syphilis is the stage diagnosed individuals. bacteria entered
Recommended publications
  • THE PHYSIOLOGY and ECOPHYSIOLOGY of EJACULATION Tropical and Subtropical Agroecosystems, Vol
    Tropical and Subtropical Agroecosystems E-ISSN: 1870-0462 [email protected] Universidad Autónoma de Yucatán México Lucio, R. A.; Cruz, Y.; Pichardo, A. I.; Fuentes-Morales, M. R.; Fuentes-Farias, A.L.; Molina-Cerón, M. L.; Gutiérrez-Ospina, G. THE PHYSIOLOGY AND ECOPHYSIOLOGY OF EJACULATION Tropical and Subtropical Agroecosystems, vol. 15, núm. 1, 2012, pp. S113-S127 Universidad Autónoma de Yucatán Mérida, Yucatán, México Available in: http://www.redalyc.org/articulo.oa?id=93924484010 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Tropical and Subtropical Agroecosystems, 15 (2012) SUP 1: S113 – S127 REVIEW [REVISIÓN] THE PHYSIOLOGY AND ECOPHYSIOLOGY OF EJACULATION [FISIOLOGÍA Y ECOFISIOLOGÍA DE LA EYACULACIÓN] R. A. Lucio1*, Y. Cruz1, A. I. Pichardo2, M. R. Fuentes-Morales1, A.L. Fuentes-Farias3, M. L. Molina-Cerón2 and G. Gutiérrez-Ospina2 1Centro Tlaxcala de Biología de la Conducta, Universidad Autónoma de Tlaxcala, Tlaxcala-Puebla km 1.5 s/n, Loma Xicotencatl, 90062, Tlaxcala, Tlax., México. 2Depto. Biología Celular y Fisiología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad Universitaria, 04510, México, D.F., México. 3Laboratorio de Ecofisiologia Animal, Departamento de Fisiologia, Instituto de Investigaciones sobre los Recursos Naturales, Universidad Michoacana de San Nicolás de Hidalgo, Av. San Juanito Itzicuaro s/n, Colonia Nueva Esperanza 58337, Morelia, Mich., México * Corresponding author ABSTRACT RESUMEN Different studies dealing with ejaculation view this Diferentes estudios enfocados en la eyaculación, process as a part of the male copulatory behavior.
    [Show full text]
  • Andrology User Handbook
    Document code: AY.P001 Version number: 7 Date of issue: 29/06/2020 USER HANDBOOK FOR ANDROLOGY SERVICES Diagnostic Semen Analysis Post Vasectomy Semen Analysis Retrograde Ejaculation Analysis Page 1 of 24 Document code: AY.P001 Version number: 7 Date of issue: 29/06/2020 Contents: 1. Introduction .................................................................................................................... 3 2. Location and Opening Times .......................................................................................... 4 3. Useful contacts ............................................................................................................... 4 4. Services provided by the laboratory ............................................................................... 5 5. Requesting semen analysis ............................................................................................ 5 6. Analysis test types .......................................................................................................... 8 6.1 Diagnostic semen analysis (DSA) test for fertility ......................................................... 8 6.1a Instructions for collection of a semen sample for DSA (fertility)............................... 9 6.1b How Diagnostic Semen Analysis assessments are reported .................................10 6.2 Retrograde Analysis ....................................................................................................11 6.2a Instructions for collection of urine for retrograde ejaculation
    [Show full text]
  • Erectile Dysfunction and Premature Ejaculation
    GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation (Text update April 2014) K. Hatzimouratidis (chair), I. Eardley, F. Giuliano, D. Hatzichristou, I. Moncada, A. Salonia, Y. Vardi, E. Wespes Eur Urol 2006 May;49(5):806-15 Eur Urol 2010 May;57(5):804-14 Eur Urol 2012 Sep;62(3):543-52 ERECTILE DYSFUNCTION Definition, epidemiology and risk factors Erectile dysfunction (ED) is the persistent inability to attain and maintain an erection sufficient to permit satisfactory sex- ual performance. Although ED is a benign disorder, it affects physical and psychosocial health and has a significant impact on the quality of life (QoL) of sufferers and their partners. There is increasing evidence that ED can be an early mani- festation of coronary artery and peripheral vascular disease; thus, ED should not be regarded only as a QoL issue but also as a potential warning sign of cardiovascular disease includ- ing lack of exercise, obesity, smoking, hypercholesterolaemia, and the metabolic syndrome. The risk of ED may be reduced by modifying these risk factors, particularly taking exercise or losing weight. Another risk factor for ED is radical prostatec- tomy (RP) in any form (open, laparoscopic, or robotic) because of the risk of cavernosal nerve injury, poor oxygenation of the corpora cavernosa, and vascular insufficiency. 130 Male Sexual Dysfunction Diagnosis and work-up Basic work-up The basic work-up (minimal diagnostic evaluation) outlined in Fig. 1 must be performed in every patient with ED. Due to the potential cardiac risks associated with sexual activity, the three Princeton Consensus Conference stratified patients with ED wanting to initiate, or resume, sexual activity into three risk categories.
    [Show full text]
  • Premature Ejaculation: Practice Essentials, Background, Pathophysiology
    2017­6­17 Premature Ejaculation: Practice Essentials, Background, Pathophysiology This site is intended for healthcare professionals Premature Ejaculation Updated: Mar 15, 2016 Author: Samuel G Deem, DO; Chief Editor: Edward David Kim, MD, FACS more... OVERVIEW Practice Essentials Premature (early) ejaculation is the most common sexual disorder in men younger than 40 years, with 30­70% of males in the United States affected to some degree at one time or another. It has historically been considered a psychological disease with no identified organic cause. Signs and symptoms Premature ejaculation can be lifelong or acquired. With lifelong premature ejaculation, the patient has experienced premature ejaculation since first beginning coitus. With acquired premature ejaculation, the patient previously had successful coital relationships and only now has developed premature ejaculation. Patient characteristics in lifelong premature ejaculation can include the following: Psychological difficulties Deep anxiety about sex that relates to 1 or more traumatic experiences encountered during development In patients with lifelong premature ejaculation, inquire about the following: Previous psychological difficulties Early sexual experiences Family relationships during childhood and adolescence Peer relationships Work or school General attitude toward sex Context of the event (eg, marital versus nonmarital) Sexual attitude and response of the female partner Nonsexual aspects of the current relationship level of involvement of the sexual partner in treatment
    [Show full text]
  • Medicine Safety “Pharmacovigilance” Fact Sheet
    MINISTRY OF MEDICAL SERVICES MINISTRY OF PUBLIC HEALTH AND SANITATION PHARMACY AND POISONS BOARD MEDICINE SAFETY “PHARMACOVIGILANCE” FACT SHEET What is medicine safety? Medicine safety, also referred to as Pharmacovigilance refers to the science of collecting, monitoring, researching, assessing and evaluating information from healthcare providers and patients on the adverse effects of medicines, biological products, herbals and traditional medicines. It aims at identifying new information about hazards, and preventing harm to patients. What is an Adverse Drug Reaction? The World Health Organization defines an adverse drug reaction (ADR) as "A response to a drug which is noxious and unintended, and which occurs at doses normally used or tested in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function". Simply put, when the doctor prescribes you medicines, he expects the desirable effects of them. The undesired effects of the medicines is the ADR or, commonly known as “side effects”. An adverse drug reaction is considered to be serious when it is suspected of causing death, poses danger to life, results in admission to hospital, prolongs hospitalization, leads to absence from productive activity, increased investigational or treatment costs, or birth defects. Age, gender, previous history of allergy or reaction, race and genetic factors, multiple medicine therapy and presence of concomitant disease processes may predispose one to adverse effects. Why monitor adverse drug reactions? Before registration and marketing of a medicine, its safety and efficacy experience is based primarily on clinical trials. Some important adverse reactions may not be detected early or may even be rare.
    [Show full text]
  • AVANDIA (Rosiglitazone Maleate Tablets), for Oral Use Ischemic Cardiovascular (CV) Events Relative to Placebo, Not Confirmed in Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS AND PRECAUTIONS ----------------------- These highlights do not include all the information needed to use • Fluid retention, which may exacerbate or lead to heart failure, may occur. AVANDIA safely and effectively. See full prescribing information for Combination use with insulin and use in congestive heart failure NYHA AVANDIA. Class I and II may increase risk of other cardiovascular effects. (5.1) • Meta-analysis of 52 mostly short-term trials suggested a potential risk of AVANDIA (rosiglitazone maleate tablets), for oral use ischemic cardiovascular (CV) events relative to placebo, not confirmed in Initial U.S. Approval: 1999 a long-term CV outcome trial versus metformin or sulfonylurea. (5.2) • Dose-related edema (5.3) and weight gain (5.4) may occur. WARNING: CONGESTIVE HEART FAILURE • Measure liver enzymes prior to initiation and periodically thereafter. Do See full prescribing information for complete boxed warning. not initiate therapy in patients with increased baseline liver enzyme levels ● Thiazolidinediones, including rosiglitazone, cause or exacerbate (ALT >2.5X upper limit of normal). Discontinue therapy if ALT levels congestive heart failure in some patients (5.1). After initiation of remain >3X the upper limit of normal or if jaundice is observed. (5.5) AVANDIA, and after dose increases, observe patients carefully for signs • Macular edema has been reported. (5.6) and symptoms of heart failure (including excessive, rapid weight gain; • Increased incidence of bone fracture was observed in long-term trials. dyspnea; and/or edema). If these signs and symptoms develop, the heart (5.7) failure should be managed according to current standards of care.
    [Show full text]
  • Pharmaceutical Sales Representatives
    [Chapter 4, 28 April] Chapter 4 Pharmaceutical sales representatives Andy Gray, Jerome Hoffman and Peter R Mansfield The presence of pharmaceutical industry sales representatives almost seems a fact of life at many modern medical centres and universities around the world. Many medical and pharmacy students come into contact with pharmaceutical industry sales representatives during their training. Later on in the careers of many health professionals, encounters with sales representatives can occur on a daily basis, taking up a substantial portion of a busy health professional s time. However, health professionals have a choice in the matter - they may choose not to see pharmaceutical sales representatives at all or they may attempt to manage such interactions.’ This chapter aims to provide information to help you make up your own mind on this issue. This choice has important consequences for health professionals practice and patients, so requires careful consideration. ’ Aims of this chapter By the end of the session based on this chapter, you should be able to answer a series of questions on your interactions with sales representatives: In what ways, if any, might I hope to benefit from meeting with sales representatives? How are sales representatives selected, trained, supported and managed? What information do sales representatives provide? How might contact with sales representatives influence me in a positive or negative way? Should I have contact with sales representatives at all? Is it possible, if I choose to have contact with sales representatives, to minimise the potential harm and maximise the potential benefit for my professional development and practice? This chapter presents evidence that we believe can be helpful in addressing these questions, and ends with a series of activities that will allow students to work on the issue in more depth.
    [Show full text]
  • Alison Bass Curriculum Vitae Current Affiliations • Associate Professor Of
    Alison Bass Curriculum Vitae Current Affiliations Associate Professor of Journalism, West Virginia University 2012-present Author, Freelance Writer and Blogger 2008-present Journalism Experience Author of forthcoming book, Getting Screwed: Sex Workers and the Law (Fall 2015) Getting Screwed takes a wide-ranging historic look at prostitution in the United States. It weaves the true stories of sex workers (past and present) together with the latest research in exploring the advisability of decriminalizing adult prostitution. To read more about this project, visit www.sexworkandthelaw.com/. Author of Side Effects: A Prosecutor, a Whistleblower and a Bestselling Antidepressant on Trial Side Effects won the NASW Science in Society Award and garnered critical acclaim from many quarters, including The New York Review of Books, The Boston Globe and The Washington Post. Published by Algonquin Books in 2008, Side Effects tells the true story of three people who exposed the deception behind the making of a bestselling drug. To read more about the book, visit www.alison-bass.com. Journalist-Blogger 2008-present My blog, at http://www.sexworkandthelaw.com/blog/ is an ongoing discussion about sex work and public health. I have also written blogs for The Huffington Post and opinion pieces for The Boston Globe about various topics including scientific misconduct and sex work. Alicia Patterson Foundation 2007-2008 Won a prestigious Alicia Patterson Fellowship to write Side Effects, a book about scientific fraud and conflicts of interest in the medical/pharmaceutical industry. CIO magazine, Executive Editor 2000-2006 Wrote and edited feature-length articles and columns for CIO, an award-winning business magazine that covers information technology.
    [Show full text]
  • Sexually Transmitted Infections Treatment Guidelines, 2021
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 70 / No. 4 July 23, 2021 Sexually Transmitted Infections Treatment Guidelines, 2021 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................1 Clinical Prevention Guidance ............................................................................2 STI Detection Among Special Populations ............................................... 11 HIV Infection ......................................................................................................... 24 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 27 Syphilis ................................................................................................................... 39 Management of Persons Who Have a History of Penicillin Allergy .. 56 Diseases Characterized by Urethritis and Cervicitis ............................... 60 Chlamydial Infections ....................................................................................... 65 Gonococcal Infections ...................................................................................... 71 Mycoplasma genitalium .................................................................................... 80 Diseases Characterized
    [Show full text]
  • Side Effects in Education
    What works may hurt: Side effects in education Yong Zhao Journal of Educational Change ISSN 1389-2843 J Educ Change DOI 10.1007/s10833-016-9294-4 1 23 Your article is protected by copyright and all rights are held exclusively by Springer Science +Business Media Dordrecht. This e-offprint is for personal use only and shall not be self- archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com”. 1 23 Author's personal copy J Educ Change DOI 10.1007/s10833-016-9294-4 What works may hurt: Side effects in education Yong Zhao1 Ó Springer Science+Business Media Dordrecht 2017 Abstract Medical research is held as a field for education to emulate. Education researchers have been urged to adopt randomized controlled trials, a more ‘‘scien- tific’’ research method believed to have resulted in the advances in medicine. But a much more important lesson education needs to borrow from medicine has been ignored. That is the study of side effects. Medical research is required to investigate both the intended effects of any medical interventions and their unintended adverse effects, or side effects.
    [Show full text]
  • The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry
    Michigan Business & Entrepreneurial Law Review Volume 8 Issue 1 2018 The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry Eugene McCarthy University of Illinois Follow this and additional works at: https://repository.law.umich.edu/mbelr Part of the Business Organizations Law Commons, Consumer Protection Law Commons, Food and Drug Law Commons, and the Rule of Law Commons Recommended Citation Eugene McCarthy, The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry, 8 MICH. BUS. & ENTREPRENEURIAL L. REV. 29 (2018). Available at: https://repository.law.umich.edu/mbelr/vol8/iss1/3 This Article is brought to you for free and open access by the Journals at University of Michigan Law School Scholarship Repository. It has been accepted for inclusion in Michigan Business & Entrepreneurial Law Review by an authorized editor of University of Michigan Law School Scholarship Repository. For more information, please contact [email protected]. THE PHARMA BARONS: CORPORATE LAW’S DANGEROUS NEW RACE TO THE BOTTOM IN THE PHARMACEUTICAL INDUSTRY Eugene McCarthy* INTRODUCTION......................................................................................... 29 I. THE RACE TO THE BOTTOM AND THE RISE OF THE ROBBER BARONS ..................................................................................... 32 A. Revising the Corporate Codes............................................ 32 B. The Emergence of Nineteenth-Century Lobbying ............. 37 C. The Robber
    [Show full text]
  • Death of a Sales Model, Or Not: Perspectives on The
    ACKNOWLEDGEMENTS We are indebted to Bryce Davis for his organization and leadership, which made this compendium possible. Thank you also to Geoff Lewis, Kate Spears, and Patrick Taaffe, our editors, and to Alizah Herman for design. And finally, we would like to thank our clients and friends, for sharing with us their stories on where they’ve been and their thoughts on the path ahead, as they lead their companies and colleagues through this period of change. Global/NA Head of Pharmaceutical and Medical Products (PMP) Michael Silber EU/HEAD OF PMP Vivian Hunt ASIA PACIFIC/HEAD OF PMP Rajesh Parekh For questions or more information, please contact Bryce Davis ([email protected]) Chicago Office New Jersey Office Orange County Office Stamford Office 21 South Clark Street 600 Campus Drive 131 Innovation Drive Three Landmark Suite 2900 Florham Park, NJ Suite 200 Square Chicago, IL 60603 07932 Irvine, CA 92617 Suite 100 Stamford, CT 06901 Los Angeles Office New York Office Silicon Valley Office 400 South Hope Street 5 East 52nd Street 3075A Hansen Way Suite 800 21st Floor Palo Alto, CA 94304 Los Angeles, CA 90071 New York, NY 10022 CONTENTS Preface 02 Introduction David Quigley Articles 03 The Few, The Proud, The Super-Productive How a ‘smart field force’ can better drive sales Laura Moran and David Quigley 09 Organization Men Understanding the challenges and serving the needs of corporatized healthcare providers Bhawana Malhotra, Nick Mills, Laura Moran, and David Quigley 15 The More the Merrier? ‘Account ownership’ and other engagement
    [Show full text]